select trial semaglutide cardiovascular outcomes non-diabetic 2023 The - A New Era in Obesity and Care Semaglutide cardiovascular outcomes align more

However, the medication is not recommended for patients with a history of medullary thyroid cancer (MTC) and MEN 2 syndrome (multiple endocrine neoplasia syndrome type 2)

Lifestyle interventions play a crucial role in neuropathy management

The medication also slows gastric emptying, which moderates the speed at which nutrients enter the bloodstream, preventing sharp blood sugar spikes that force the pancreas to work harder

By targeting these brain signals, semaglutide controls hunger and satiety

Authors of the study that found an association between semaglutide and suicidal ideation, did not find the corresponding link in their analysis of liraglutide